An Aptamer-Based Protein Biochip

Stadtherr, Karin; Wolf, Hans; Lindner, Petra

doi:10.1021/ac0483421

Cited by 124 publications

(103 citation statements)

References 25 publications

(35 reference statements)

Supporting

Mentioning

103

Contrasting

Order By: Relevance

“…[56][57][58][59] Lindner and co-workers 58 immobilized 5 -amino-modified DNA aptamers via glutaraldehyde linkage on amino-silanized glass substrates and compared the binding affinity of aptamer microarrays with antibody microarrays which are both selective towards the same fluorescently-labeled thrombin target. It was clearly demonstrated that aptamer-based analyte recognition was at least as sensitive as antibody-based detection.…”

Section: Iii1 Nucleic Acid Aptamer Microarraysmentioning

confidence: 99%

Microarray methods for protein biomarker detection

Lee

Wark

Corn

2008

Analyst

137

108

View full text Add to dashboard Cite

The application of protein biomarkers as an aid for the detection and treatment of diseases has been subject to intensified interest in recent years. The quantitative assaying of protein biomarkers in easily obtainable biological fluids such as serum and urine offers the opportunity to improve patient care via earlier and more accurate diagnoses in a convenient, non-invasive manner as well as providing a potential route towards more individually targeted treatment. Essential to achieving progress in biomarker technology is the ability to screen large numbers of proteins simultaneously in a single experiment with high sensitivity and selectivity. In this article, we highlight recent progress in the use of microarrays for high-throughput biomarker profiling and discuss some of the challenges associated with these efforts. I IntroductionThe discovery of protein biomarkers whose change in expression level or state correlates with the progression of a disease is becoming increasingly important. Once validated, proposed biomarkers can be involved in achieving an earlier diagnosis, differentiating between disease types with greater accuracy, and assessing response to treatment. Prominent examples of biomarkers include proteins that are associated with a variety of cancers, 1-4 as well as heart, 5,6 renal, 7,8 andAlzheimer's 9,10 diseases.Most biomarker studies reported to date have focused on serum-, plasmaand urine-based samples. A number of other possibilities include saliva, tears, breath condensates, cerebrospinal fluid and tissue lysates extracted from biopsy samples. There are several excellent reviews detailing biomarker discovery and validation. [11][12][13][14][15] The potential benefits of biomarkers have greatly motivated both academic and industry researchers to apply new proteomic technologies for biomarker discovery and to develop quantitative analytical methodologies for rapid and sensitive biomarker detection. Many clinically relevant biomarkers reside in blood at picomolar concentrations and lower, which is five to seven orders of magnitude lower than the most abundant plasma proteins. Therefore, protein detection with high specificity and sensitivity is required; unfortunately, no universal ultrasensitive enzymatic amplification method (such as PCR for the case of nucleic acid detection) exists for proteins. Additionally, it is desirable to screen multiple proteins simultaneously in a single sample. Multiplexed measurements are attractive not only for economic reasons but also for identifying characteristic signal patterns associated with the relative changes in entire sets of proteins as this will provide much more insight and diagnostic accuracy than individual biomarker measurements.hyejinlee@knu.ac.kr. 14,19,[24][25][26][27][28][29][30] Although microarray methods are wellestablished for high-throughput nucleic acid studies, their application for protein detection has been limited by issues such as the surface immobilization of protein capture probes without loss in bioactivity as well a...

show abstract

Section: Iii1 Nucleic Acid Aptamer Microarraysmentioning

confidence: 99%

Microarray methods for protein biomarker detection

Lee

Wark

Corn

2008

Analyst

137

108

View full text Add to dashboard Cite

show abstract

“…This is 10 5 lower than the most abundant immunoglobulin, IgG, which is normally present at approximately 100 μM in human serum [11]. The IgE aptamer has previously been used for label-free [12,13] and fluorescent-labeled [14,15] detection of IgE in simple solution, providing detectability down to 10 −10 M IgE (corresponding to 5 fmol using a 50 μL aliquot in the case of one immobilized aptamer sensor [13]). The use of fluorescent-labeled IgE aptamer in affinity capillary electrophoresis gave a detection limit of 46 pM IgE in simple solution, but application to human serum yielded detectable signals only for serum that was spiked with 5 nM IgE and not for native IgE in the serum [16].…”

Section: Introductionmentioning

confidence: 99%

“…In the present work, we achieved capture and detection of native IgE in human serum and found that dilution of the serum by at least 10 3 -fold allowed detection of native IgE with little interference from other serum proteins. Detectability compares favorably with the commercial antibody-based ELISA kit (Human IgE ELISA Quantitation Kit, Bethyl Laboratories, Montgomery, TX) that offers 75 pM detection [14].…”

Section: Introductionmentioning

confidence: 99%

Affinity Capture and Detection of Immunoglobulin E in Human Serum Using an Aptamer-Modified Surface in Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry

et al. 2006

View full text Add to dashboard Cite

Capture and detection of Immunoglobulin E (IgE) in simple solution and in human serum using an aptamer-modified probe surface for affinity Matrix-Assisted Laser Desorption-Ionization Mass Spectroscopy (affinity MALDI-MS) detection is reported. Detectable signals were obtained for 1 amol of IgE applied either in a single, 1 μL application of 1 pM IgE or after 10 successive, 1 μL applications of 100 fM IgE. In both cases, the surface was rinsed after each application of IgE to remove sample concomitants including salts and free or non-specifically associated proteins. Detection of native IgE, which is the least abundant of the serum immunoglobulins and occurs at sub-nM levels, in human serum was demonstrated and interference from the high abundance immunoglobulins and albumin was investigated. The aptamermodified surface showed high selectivity towards immunoglobulins in serum, with no significant interference from serum albumin. Addition of IgE to the serum suppressed the signals from the other immunoglobulins, confirming the expected selectivity of the aptamer surface towards IgE. Dilution of the serum increased the selectivity toward IgE; the protein was detected without interference in a 10,000-fold dilution of the serum, which is consistent with detection of IgE at amol (pM) levels in standard solutions.

show abstract

“…To confer structural robustness in the molecular recognition elements suited for the planar microarray sensing platform, aptamers have successfully been demonstrated as the next viable option in recent years. [29,30] Ellington and coworkers, have pioneered the design and fabrication of aptamer microarrays, [31][32][33] in which the group has enabled an automated protocol for aptamer generation.. It is projected that with the augment of automated SELEX selection process, nucleic acid aptamers can now be generated in days, rather than weeks to months.…”

Section: Aptasensing Platforms and Detection Assaysmentioning

confidence: 99%

Aptasensors for biosecurity applications

Fischer

Tarasow

Tok

2007

Current Opinion in Chemical Biology

View full text Add to dashboard Cite

SUMMARY:Nucleic acid aptamers have found steadily increased utility and application steadily over the last decade. In particular, aptamers have been touted as a valuable complement to and in some cases replacement for antibodies due to their structural and functional robustness as well as their ease in generation and synthesis. They are thus attractive for biosecurity applications, e.g. pathogen detection, and are especially well suited since their in vitro generation process does not require infection of any host systems. Herein we provide a brief overview of the aptamers generated against biopathogens over the last few years. In addition, a few recently described detection platforms using aptamers (aptasensors) and potentially suitable for biosecurity applications will be discussed.

show abstract

An Aptamer-Based Protein Biochip

Cited by 124 publications

References 25 publications

Microarray methods for protein biomarker detection

Microarray methods for protein biomarker detection

Affinity Capture and Detection of Immunoglobulin E in Human Serum Using an Aptamer-Modified Surface in Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry

Aptasensors for biosecurity applications

Contact Info

Product

Resources

About